Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Consistent success in life-supporting porcine cardiac xenotransplantation.

Längin M, Mayr T, Reichart B, Michel S, Buchholz S, Guethoff S, Dashkevich A, Baehr A, Egerer S, Bauer A, Mihalj M, Panelli A, Issl L, Ying J, Fresch AK, Buttgereit I, Mokelke M, Radan J, Werner F, Lutzmann I, Steen S, Sjöberg T, Paskevicius A, Qiuming L, Sfriso R, Rieben R, Dahlhoff M, Kessler B, Kemter E, Klett K, Hinkel R, Kupatt C, Falkenau A, Reu S, Ellgass R, Herzog R, Binder U, Wich G, Skerra A, Ayares D, Kind A, Schönmann U, Kaup FJ, Hagl C, Wolf E, Klymiuk N, Brenner P, Abicht JM.

Nature. 2018 Dec;564(7736):430-433. doi: 10.1038/s41586-018-0765-z. Epub 2018 Dec 5.

PMID:
30518863
2.

Regeneration After Radiation- and Immune-Mediated Tissue Injury Is Not Enhanced by Type III Interferon Signaling.

Fischer JC, Lin CC, Heidegger S, Wintges A, Schlapschy M, Beudert M, Combs SE, Bassermann F, Skerra A, Haas T, Poeck H.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):970-976. doi: 10.1016/j.ijrobp.2018.11.038. Epub 2018 Nov 29.

PMID:
30503785
3.

An engineered lipocalin that tightly complexes the plant poison colchicine for use as antidote and in bioanalytical applications.

Barkovskiy M, Ilyukhina E, Dauner M, Eichinger A, Skerra A.

Biol Chem. 2019 Feb 25;400(3):351-366. doi: 10.1515/hsz-2018-0342.

PMID:
30517073
4.

PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice.

Xia Y, Schlapschy M, Morath V, Roeder N, Vogt EI, Stadler D, Cheng X, Dittmer U, Sutter K, Heikenwalder M, Skerra A, Protzer U.

Antiviral Res. 2019 Jan;161:134-143. doi: 10.1016/j.antiviral.2018.11.003. Epub 2018 Nov 12.

PMID:
30439382
5.

Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.

Nganou-Makamdop K, Billingsley JM, Yaffe Z, O'Connor G, Tharp GK, Ransier A, Laboune F, Matus-Nicodemos R, Lerner A, Gharu L, Robertson JM, Ford ML, Schlapschy M, Kuhn N, Lensch A, Lifson J, Nason M, Skerra A, Schreiber G, Bosinger SE, Douek DC.

PLoS Pathog. 2018 Aug 24;14(8):e1007246. doi: 10.1371/journal.ppat.1007246. eCollection 2018 Aug.

6.

A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery.

Hoffmann K, Milech N, Juraja SM, Cunningham PT, Stone SR, Francis RW, Anastasas M, Hall CM, Heinrich T, Bogdawa HM, Winslow S, Scobie MN, Dewhurst RE, Florez L, Ong F, Kerfoot M, Champain D, Adams AM, Fletcher S, Viola HM, Hool LC, Connor T, Longville BAC, Tan YF, Kroeger K, Morath V, Weiss GA, Skerra A, Hopkins RM, Watt PM.

Sci Rep. 2018 Aug 22;8(1):12538. doi: 10.1038/s41598-018-30790-2.

7.

Reprogramming Human Siderocalin To Neutralize Petrobactin, the Essential Iron Scavenger of Anthrax Bacillus.

Dauner M, Eichinger A, Lücking G, Scherer S, Skerra A.

Angew Chem Int Ed Engl. 2018 Oct 26;57(44):14619-14623. doi: 10.1002/anie.201807442. Epub 2018 Oct 2.

PMID:
30063283
8.

Anticalin® Proteins as Therapeutic Agents in Human Diseases.

Rothe C, Skerra A.

BioDrugs. 2018 Jun;32(3):233-243. doi: 10.1007/s40259-018-0278-1. Review.

9.

Structural Basis for the Specific Cotranslational Incorporation of p-Boronophenylalanine into Biosynthetic Proteins.

Schiefner A, Nästle L, Landgraf M, Reichert AJ, Skerra A.

Biochemistry. 2018 May 8;57(18):2597-2600. doi: 10.1021/acs.biochem.8b00171. Epub 2018 Apr 24.

PMID:
29668275
10.

Anticalins Reveal High Plasticity in the Mode of Complex Formation with a Common Tumor Antigen.

Schiefner A, Gebauer M, Richter A, Skerra A.

Structure. 2018 Apr 3;26(4):649-656.e3. doi: 10.1016/j.str.2018.02.003. Epub 2018 Mar 8.

PMID:
29526433
11.

Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis.

Griffiths K, Habiel DM, Jaffar J, Binder U, Darby WG, Hosking CG, Skerra A, Westall GP, Hogaboam CM, Foley M.

Sci Rep. 2018 Feb 16;8(1):3212. doi: 10.1038/s41598-018-20811-5.

12.

Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models.

Friedrich L, Kornberger P, Mendler CT, Multhoff G, Schwaiger M, Skerra A.

Biol Chem. 2018 Feb 23;399(3):235-252. doi: 10.1515/hsz-2017-0207.

PMID:
29140786
13.

Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.

Gebauer M, Skerra A.

Bioorg Med Chem. 2018 Jun 1;26(10):2882-2887. doi: 10.1016/j.bmc.2017.09.016. Epub 2017 Sep 15.

PMID:
29102080
14.

The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.

Breibeck J, Skerra A.

Biopolymers. 2018 Jan;109(1). doi: 10.1002/bip.23069. Epub 2017 Oct 27.

15.

Rational Design of an Anticalin-Type Sugar-Binding Protein Using a Genetically Encoded Boronate Side Chain.

Edwardraja S, Eichinger A, Theobald I, Sommer CA, Reichert AJ, Skerra A.

ACS Synth Biol. 2017 Dec 15;6(12):2241-2247. doi: 10.1021/acssynbio.7b00199. Epub 2017 Oct 18.

PMID:
28937743
16.

Tight Molecular Recognition of Benzo[a]pyrene by a High-Affinity Antibody.

Eichinger A, Neumaier I, Pschenitza M, Niessner R, Knopp D, Skerra A.

Angew Chem Int Ed Engl. 2017 Aug 21;56(35):10592-10597. doi: 10.1002/anie.201703893. Epub 2017 Jul 21.

PMID:
28603847
17.

Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.

Nováková Z, Foss CA, Copeland BT, Morath V, Baranová P, Havlínová B, Skerra A, Pomper MG, Barinka C.

Prostate. 2017 May;77(7):749-764. doi: 10.1002/pros.23311. Epub 2017 Mar 1.

PMID:
28247415
18.

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I, Weinstock C, Simmet T, Ricklin D, Lambris JD, Skerra A, Anliker M, Schmidt CQ.

Blood. 2017 Feb 23;129(8):970-980. doi: 10.1182/blood-2016-08-732800. Epub 2016 Dec 27.

19.

Aligning, analyzing, and visualizing sequences for antibody engineering: Automated recognition of immunoglobulin variable region features.

Jarasch A, Skerra A.

Proteins. 2017 Jan;85(1):65-71. doi: 10.1002/prot.25193. Epub 2016 Nov 20.

PMID:
27770557
20.

PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.

Kuhn N, Schmidt CQ, Schlapschy M, Skerra A.

Bioconjug Chem. 2016 Oct 19;27(10):2359-2371. Epub 2016 Sep 26.

PMID:
27598771
21.

Engineering of alanine dehydrogenase from Bacillus subtilis for novel cofactor specificity.

Lerchner A, Jarasch A, Skerra A.

Biotechnol Appl Biochem. 2016 Sep;63(5):616-624. doi: 10.1002/bab.1414. Epub 2015 Sep 11.

PMID:
26202482
22.

Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity.

Chhabra KH, Adams JM, Jones GL, Yamashita M, Schlapschy M, Skerra A, Rubinstein M, Low MJ.

Mol Metab. 2016 Aug 5;5(10):869-881. doi: 10.1016/j.molmet.2016.07.012. eCollection 2016 Oct.

23.

Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.

Gande SL, Saxena K, Sreeramulu S, Linhard V, Kudlinzki D, Heinzlmeir S, Reichert AJ, Skerra A, Kuster B, Schwalbe H.

Chembiochem. 2016 Dec 2;17(23):2257-2263. doi: 10.1002/cbic.201600483. Epub 2016 Nov 9.

PMID:
27685543
24.

Comparison of enzymatic properties and small molecule inhibition of γ-glutamyltranspeptidases from pathogenic and commensal bacteria.

Bolz C, Bach NC, Meyer H, Müller G, Dawidowski M, Popowicz G, Sieber SA, Skerra A, Gerhard M.

Biol Chem. 2017 Mar;398(3):341-357. doi: 10.1515/hsz-2016-0198.

PMID:
27636829
25.

Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion.

Lerchner A, Daake M, Jarasch A, Skerra A.

Protein Eng Des Sel. 2016 Dec;29(12):557-562. Epub 2016 Aug 29.

PMID:
27578886
26.
27.

Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion.

Mendler CT, Feuchtinger A, Heid I, Aichler M, D'Alessandria C, Pirsig S, Blechert B, Wester HJ, Braren R, Walch A, Skerra A, Schwaiger M.

J Nucl Med. 2016 Dec;57(12):1971-1977. Epub 2016 Jul 14.

28.

Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.

Bolze F, Bast A, Mocek S, Morath V, Yuan D, Rink N, Schlapschy M, Zimmermann A, Heikenwalder M, Skerra A, Klingenspor M.

Diabetologia. 2016 Sep;59(9):2005-12. doi: 10.1007/s00125-016-4004-6. Epub 2016 Jun 7.

PMID:
27272237
29.

ANTICALIgN: visualizing, editing and analyzing combined nucleotide and amino acid sequence alignments for combinatorial protein engineering.

Jarasch A, Kopp M, Eggenstein E, Richter A, Gebauer M, Skerra A.

Protein Eng Des Sel. 2016 Jul;29(7):263-70. doi: 10.1093/protein/gzw016. Epub 2016 May 30.

PMID:
27261456
30.

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.

Rauth S, Hinz D, Börger M, Uhrig M, Mayhaus M, Riemenschneider M, Skerra A.

Biochem J. 2016 Jun 1;473(11):1563-78. doi: 10.1042/BCJ20160114. Epub 2016 Mar 30.

31.

Structural basis for cellulose binding by the type A carbohydrate-binding module 64 of Spirochaeta thermophila.

Schiefner A, Angelov A, Liebl W, Skerra A.

Proteins. 2016 Jun;84(6):855-8. doi: 10.1002/prot.25010. Epub 2016 Mar 9.

PMID:
26868291
32.

Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).

Barinka C, Ptacek J, Richter A, Novakova Z, Morath V, Skerra A.

Protein Eng Des Sel. 2016 Mar;29(3):105-15. doi: 10.1093/protein/gzv065. Epub 2016 Jan 21.

PMID:
26802163
33.

Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.

Gille H, Hülsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM, Skerra A.

Angiogenesis. 2016 Jan;19(1):79-94. doi: 10.1007/s10456-015-9490-5. Epub 2015 Dec 9.

PMID:
26650228
34.

Long-Acting PASylated Leptin Ameliorates Obesity by Promoting Satiety and Preventing Hypometabolism in Leptin-Deficient Lep(ob/ob) Mice.

Bolze F, Morath V, Bast A, Rink N, Schlapschy M, Mocek S, Skerra A, Klingenspor M.

Endocrinology. 2016 Jan;157(1):233-44. doi: 10.1210/en.2015-1519. Epub 2015 Oct 22.

PMID:
26492472
35.

Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas.

Albrecht V, Richter A, Pfeiffer S, Gebauer M, Lindner S, Gieser E, Schüller U, Schichor C, Gildehaus FJ, Bartenstein P, Tonn JC, Skerra A, Glass R.

Int J Cancer. 2016 Mar 1;138(5):1269-80. doi: 10.1002/ijc.29874. Epub 2015 Oct 15.

36.

Optimisation of a system for the co-translational incorporation of a keto amino acid and its application to a tumour-specific Anticalin.

Reichert AJ, Poxleitner G, Dauner M, Skerra A.

Protein Eng Des Sel. 2015 Dec;28(12):553-65. doi: 10.1093/protein/gzv048. Epub 2015 Sep 23.

PMID:
26405058
37.

Stability engineering of the Geobacillus stearothermophilus alcohol dehydrogenase and application for the synthesis of a polyamide 12 precursor.

Kirmair L, Seiler DL, Skerra A.

Appl Microbiol Biotechnol. 2015 Dec;99(24):10501-13. doi: 10.1007/s00253-015-6930-5. Epub 2015 Sep 2.

PMID:
26329849
38.

Structural Basis for the Interconversion of Maltodextrins by MalQ, the Amylomaltase of Escherichia coli.

Weiss SC, Skerra A, Schiefner A.

J Biol Chem. 2015 Aug 28;290(35):21352-64. doi: 10.1074/jbc.M115.667337. Epub 2015 Jul 2.

39.

⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.

Mendler CT, Gehring T, Wester HJ, Schwaiger M, Skerra A.

J Nucl Med. 2015 Jul;56(7):1112-8. doi: 10.2967/jnumed.114.149690. Epub 2015 May 21.

40.

PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy.

Morath V, Bolze F, Schlapschy M, Schneider S, Sedlmayer F, Seyfarth K, Klingenspor M, Skerra A.

Mol Pharm. 2015 May 4;12(5):1431-42. doi: 10.1021/mp5007147. Epub 2015 Apr 10.

41.

Crystal structure of the human odorant binding protein, OBPIIa.

Schiefner A, Freier R, Eichinger A, Skerra A.

Proteins. 2015 Jun;83(6):1180-4. doi: 10.1002/prot.24797. Epub 2015 Apr 4.

PMID:
25810031
42.

The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds.

Schiefner A, Skerra A.

Acc Chem Res. 2015 Apr 21;48(4):976-85. doi: 10.1021/ar5003973. Epub 2015 Mar 10. Review.

PMID:
25756749
43.

The Strep-tag system for one-step affinity purification of proteins from mammalian cell culture.

Schmidt T, Skerra A.

Methods Mol Biol. 2015;1286:83-95. doi: 10.1007/978-1-4939-2447-9_8.

PMID:
25749948
44.

Design and characterization of a modular membrane protein anchor to functionalize the moss Physcomitrella patens with extracellular catalytic and/or binding activities.

Morath V, Truong DJ, Albrecht F, Polte I, Ciccone RA, Funke LF, Reichart L, Wolf CG, Brunner AD, Fischer K, Schneider PC, Brüggenthies JB, Fröhlich F, Wiedemann G, Reski R, Skerra A.

ACS Synth Biol. 2014 Dec 19;3(12):990-4. doi: 10.1021/sb5000302.

PMID:
25524107
45.

High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.

Mendler CT, Friedrich L, Laitinen I, Schlapschy M, Schwaiger M, Wester HJ, Skerra A.

MAbs. 2015;7(1):96-109. doi: 10.4161/19420862.2014.985522.

46.

The dimeric crystal structure of the human fertility lipocalin glycodelin reveals a protein scaffold for the presentation of complex glycans.

Schiefner A, Rodewald F, Neumaier I, Skerra A.

Biochem J. 2015 Feb 15;466(1):95-104. doi: 10.1042/BJ20141003.

PMID:
25422905
47.

Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.

Harari D, Kuhn N, Abramovich R, Sasson K, Zozulya AL, Smith P, Schlapschy M, Aharoni R, Köster M, Eilam R, Skerra A, Schreiber G.

J Biol Chem. 2014 Oct 17;289(42):29014-29. doi: 10.1074/jbc.M114.602474. Epub 2014 Sep 5.

48.

PAS-cal: A repetitive peptide sequence calibration standard for MALDI mass spectrometry.

Maier SK, Bashkueva K, Rösli C, Skerra A, Kuster B.

Proteomics. 2014 Nov;14(21-22):2427-31. doi: 10.1002/pmic.201400199. Epub 2014 Sep 25.

PMID:
25143245
49.

PAS-cal: a generic recombinant peptide calibration standard for mass spectrometry.

Breibeck J, Serafin A, Reichert A, Maier S, Küster B, Skerra A.

J Am Soc Mass Spectrom. 2014 Aug;25(8):1489-97. doi: 10.1007/s13361-014-0902-3. Epub 2014 May 28.

50.

Derivatization of antibody Fab fragments: a designer enzyme for native protein modification.

Liebscher S, Kornberger P, Fink G, Trost-Gross EM, Höss E, Skerra A, Bordusa F.

Chembiochem. 2014 May 26;15(8):1096-100. doi: 10.1002/cbic.201400059. Epub 2014 Apr 29.

PMID:
24782039

Supplemental Content

Loading ...
Support Center